BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Johnson & Johnson Deepens Hong Kong Commitment with Strategic Partnership to Accelerate Healthcare Innovation

Building on more than five decades in Hong Kong, Johnson & Johnson is committed to advancing better health through science, innovation and collaboratio...

October 26, 2026 | News

Zai Lab’s Zoci–Atezolizumab Combination Delivers 81.8% Response Rate in First-Line Small Cell Lung Cancer

At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an est...

October 26, 2026 | News

Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer

Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...

October 23, 2026 | News

Insilico Medicine Hits First AI-Driven Oncology Milestone in $888 Million Servier Collaboration

Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reach...

October 22, 2026 | News

Ascletis Reports Promising Preclinical Data for Once-Weekly Oral Obesity Treatments, Advances US Phase 1 Trial

Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combina...

October 21, 2026 | News

Innovent’s SYCUME Meets Primary Endpoint in Phase III Trial for Inactive Thyroid Eye Disease in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

October 12, 2026 | News

Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...

October 12, 2026 | News

Suzhou Ribo Life Science Submits Phase I Clinical Trial Application in EU for siRNA Obesity Therapy RBD3133

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission...

October 09, 2026 | News

12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On

Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...

October 07, 2026 | Analysis

Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer

Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...

September 29, 2026 | News

XtalPi Files US FDA IND for AI-Designed Gut-Restricted Pan-TRK Inhibitor KQTD-126

This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...

September 28, 2026 | News

Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies

- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...

September 24, 2026 | News

Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial

Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...

September 04, 2026 | News

Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

September 04, 2026 | News

Stay Connected